 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
Alert Number 152
Date: February 24, 2024
A couple of weeks ago we reviewed a new clinical trial at UPMC, one that took a fresh approach to the chemo-immunotherapy combination of F, C and R. We dubbed this new trial “FCR Lite”, because it attempts to reduce the toxicity of the combination by decreasing the amounts of the chemotherapy drugs fludarabine (“F”) and cyclophosphamide (“C”), and increasing the amount of Rituxan (“R”), compared to the dosages used in “FCR Classic” pioneered at M. D. Anderson. You can read the details of this trial by clicking on the following link: FCR Lite.
Now we have a first person account of a patient going through this trial. In keeping with our previous practice, the patient’s privacy is maintained by using a fictitious name and persona. “Forest Gump” is a CLL patient after my own heart. He is a runner (hence the name he chose) and believes in keeping himself fit. But I think you will agree therapy was in the cards and we thank him for volunteering for this important trial. You can read his individual take on this approach, as well as view detailed charts of his blood work from the date of diagnosis to right up to now, by visiting our website clltopics.org. “Forest” is part way through the protocol. We will bring you updates along the way. Please join me in wishing Forest good luck and thanking him for sharing his experiences with us.
If any of you wish to contact Forest, please send the emails to 
and we will forward them to our intrepid volunteer.
Be well,
Chaya
____________
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
